Last reviewed · How we verify

Anhydrous Amiloride Hydrochloride

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Anhydrous Amiloride Hydrochloride is a Potassium-sparing diuretic Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Edema associated with congestive heart failure, Hypertension, Hypokalemia prevention in patients on loop or thiazide diuretics.

Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium.

Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium. Used for Edema associated with congestive heart failure, Hypertension, Hypokalemia prevention in patients on loop or thiazide diuretics.

At a glance

Generic nameAnhydrous Amiloride Hydrochloride
SponsorAssistance Publique - Hôpitaux de Paris
Drug classPotassium-sparing diuretic
TargetEpithelial sodium channel (ENaC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Amiloride acts as an epithelial sodium channel (ENaC) inhibitor in the distal tubule and collecting duct of the kidney. By blocking sodium reabsorption, it promotes natriuresis and diuresis while preventing potassium loss, making it useful in conditions requiring fluid removal without hypokalemia. It is often used in combination with loop or thiazide diuretics to counteract their potassium-wasting effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anhydrous Amiloride Hydrochloride

What is Anhydrous Amiloride Hydrochloride?

Anhydrous Amiloride Hydrochloride is a Potassium-sparing diuretic drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Edema associated with congestive heart failure, Hypertension, Hypokalemia prevention in patients on loop or thiazide diuretics.

How does Anhydrous Amiloride Hydrochloride work?

Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium.

What is Anhydrous Amiloride Hydrochloride used for?

Anhydrous Amiloride Hydrochloride is indicated for Edema associated with congestive heart failure, Hypertension, Hypokalemia prevention in patients on loop or thiazide diuretics.

Who makes Anhydrous Amiloride Hydrochloride?

Anhydrous Amiloride Hydrochloride is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What drug class is Anhydrous Amiloride Hydrochloride in?

Anhydrous Amiloride Hydrochloride belongs to the Potassium-sparing diuretic class. See all Potassium-sparing diuretic drugs at /class/potassium-sparing-diuretic.

What development phase is Anhydrous Amiloride Hydrochloride in?

Anhydrous Amiloride Hydrochloride is FDA-approved (marketed).

What are the side effects of Anhydrous Amiloride Hydrochloride?

Common side effects of Anhydrous Amiloride Hydrochloride include Hyperkalemia, Headache, Dizziness, Nausea, Muscle weakness.

What does Anhydrous Amiloride Hydrochloride target?

Anhydrous Amiloride Hydrochloride targets Epithelial sodium channel (ENaC) and is a Potassium-sparing diuretic.

Related